HDAC8 and neoplasm: The combination of small molecule HDAC inhibitor Panobinostat and PCI-30451 significantly reduced tumor burden and enhances the sensitivity to BRAF inhibitors proving HDAC8 inhibitors as a promising role in therapeutics [65].